CommercialCoverageLow impact
06.02.43b, Proteomic (Protein)-Based Testing for the Evaluation of Ovarian (Adnexal) Masses Using OVA1® Test and Risk of Ovarian Malignancy Algorithm (ROMA™)
Independence Blue Cross·OB-GYN, Oncology·Pharmacy
Effective date
Sep 3, 2025
We identified it
Jun 19, 2026
Summary
This is a policy reissue for proteomic testing to evaluate ovarian masses, including OVA1® and ROMA™ tests. The policy will be reissued effective September 3, 2025, with posting on September 30, 2025.
Action Required
By September 3, 2025: Review updated policy 06.02.43b for proteomic testing of ovarian masses (OVA1® and ROMA™) when posted on September 30, 2025. Billing team should verify any changes to coverage criteria or prior authorization requirements for these specialized diagnostic tests.